Biomoda Files Patent Application

07.20.2010 — 8:00 am

ALBUQUERQUE, N.M.–Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD – News)  filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

Biomoda’s CyPath® reagents for the early detection of cancers is based on meso-tetra (4 carboxyphenyl) porphine or TCPP, a porphyrin compound that binds to cancer cells and fluoresces under specific frequencies of light. The new patent application provides a system for verifying the spectral signature of TCPP optically and measuring the photon emission rate of TCPP-stained cancerous and precancerous cells.

“We now have an objective methodology that can be used by lab technicians anywhere in the world to accurately and inexpensively read CyPath® reagent-labeled tissue samples,” said Biomoda President John Cousins. “Previously, we had to rely on cytopathologists to look at each and every sample to determine whether there were cancer cells. This patent gives us a measurable, quantitative system that opens the door for the CyPath® assay to be used to screen large populations for cancer and pre-cancerous conditions. Diagnosing cancer even before a tumor has formed will have an exponential effect on survivability.”

Biomoda is nearing completion of the pilot study on the CyPath® assay as a diagnostic for early-stage lung cancer. Pending Food and Drug Administration approval, CyPath® reagents are for investigational use only.

Titled “System and Method for Analyzing Samples Labeled with 5, 10, 15, 20 Tetrakis (4-Carboxyphenyl) Porphine (TCPP),” the U.S. and foreign patent applications build on the science underlying Biomoda’s cytology-based diagnostic. Originally developed at Los Alamos National Laboratory, the TCPP platform is the foundation for several Biomoda product lines still in the development stage.

About Biomoda

Biomoda (www.biomoda.com) focuses on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 31, 2009. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

Useful Links

Site Map Contact Us